Skip to main content
SpringerLink
Log in

DTPa-HBV-IPV/Hib vaccine: profile report

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Curran MP, Goa KL. DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa). Drugs 2003; 63(7): 673–82

    Article  PubMed  CAS  Google Scholar 

  2. Schmitt H-J. DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): a viewpoint by Heinz-Josef Schmitt. Drugs 2003; 63(7): 683

    Article  Google Scholar 

  3. Halperin SA. DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa): a viewpoint by Scott A. Halperin. Drugs 2003; 63(7): 683–4

    Article  Google Scholar 

  4. Meyerhoff AS, Weniger BG, Jacobs RJ. Economic value to parents of reducing the pain and emotional distress of childhood vaccine injections. Pediatr Infect Dis J 2001 Nov; 20 (11 Suppl.): S57–62

    PubMed  CAS  Google Scholar 

  5. Rappuoli R, Locht C, Poolman J, et al. European Commission COST/STD Initiative. Report of the expert panel VIII. New vaccines, especially new combined vaccines. Vaccine 1996 May; 14(7): 691–700

    Article  PubMed  CAS  Google Scholar 

  6. Hadler SC. Cost benefit of combining antigens. Biologicals 1994 Dec; 22(4): 415–8

    Article  PubMed  CAS  Google Scholar 

  7. GlaxoSmithKline. Summary of product characteristics (Infanrix hexa). Rixensart: GlaxoSmithKline, 2002

  8. Avdicova M, Prikazsky VV, Hudeckova H, et al. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HB V- IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 2002 Nov; 161(11): 581–7

    Article  PubMed  CAS  Google Scholar 

  9. Schmitt HJ, Knuf M, Ortiz E, et al. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 2000 Sep; 137(3): 304–12

    Article  PubMed  CAS  Google Scholar 

  10. Blatter MM, Reisinger KS, Terwelp DR, et al. Immunogenicity of a combined diptheria-tetanus-acellular pertussis (DT-tricomponent Pa)-Hepatitis B (HB)-inactivated poliovirus (IPV) admixed with Haemophilus influenzae type b (Hib) vaccine in infants. Pediatr Res 1998;43:A141

    Google Scholar 

  11. Pichichero ME, Blatter MM, Reisinger KS, et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B- inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 2002 Sep; 21(9): 854–9

    Article  PubMed  Google Scholar 

  12. Poolman J, Kaufhold A, De Grave D, et al. Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine 2001 Mar 21; 19 (17–19): 2280–5

    Article  PubMed  CAS  Google Scholar 

  13. Crovari P, Zepp F, Dentico P, et al. Immunogenicity and reactogenicity of combined DTPA-HBV-IPV/HIB vaccine compared to concomitant administered DTPA-HBV-IPV and HIB vaccines given at 3, 5, and 11 months of age. Proceedings of the 19th Annual Meeting of the European Society for Paediatric Infectious Diseases (EPSID); 2001 Mar 26–28; Istanbul

  14. Zepp F, Meyer CU, Kowalzol F, et al. Evaluation of the immunological memory induced by primary vaccination with Haemophilus influenzae type b (Hib) tetanus conjugate vaccine co-administered with various DTPa-based vaccines [abstract no. 242]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco (CA), 359

  15. Schmitt HJ, Petersen G, Corsaro B, et al. Immunogenicity and safety of a 7-valent pneumococcal conjugate vaccine (Prevenar) coadministered with a DTaP-IPV-HBV/Hib vaccine (Infanrix hexa). 42nd Interscience Conference on Anti-microbial Agents and Chemotherapy; 2002 Sep 27–30; San Diego (CA), 242

  16. Saenger R, Dobbelaere L, Schuerman L. Immunogenicity and safety of DTPa-HB V-IPV/HIB coadministered with 7-valent pneumococcal conjugate vaccine [abstract]. Proceedings of the 3rd World Congress of Pediatric Infectious Diseases; 2002 Nov 19–23; Santiago

  17. Schmitt HJ, von Kries R, Hassenpflug B, et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J 2001 Aug; 20(8): 767–74

    Article  PubMed  CAS  Google Scholar 

  18. Keller-Stanislawski B, Hartmann K. Auswertung der Meldungen von Verdachtsfallen auf Impf komplikationen nach dem Infektionsschutzgestez. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2002; 45: 344–54

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

DTPa-HBV-IPV/Hib vaccine: profile report. Drugs Ther. Perspect 19, 7–9 (2003). https://doi.org/10.2165/00042310-200319060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319060-00003

Keywords

Search

Navigation